JDRF welcomes Disability Advisory Committee’s recommendation that all Canadians needing life-sustaining therapy should automatically meet the criteria for the Disability Tax Credit and urges the Government to adopt this approach
TORONTO, May 24, 2019 (GLOBE NEWSWIRE) — JDRF Canada, the leading global funder of type 1 diabetes (T1D) research, welcomes the release of the Disability Advisory Committee’s (DAC) First Annual Report, in particular, the DAC’s recommendation that all Canadians receiving life-sustaining therapy should qualify for the Disability Tax Credit (DTC). The DAC was established in late 2017 by the Minister of National Revenue following successful efforts by JDRF Canada and Diabetes Canada to restore access to the DTC for more than a thousand adults with type 1 diabetes being denied due to a change in eligibility. JDRF calls on the Government to implement these recommendations as soon as possible.
“We are very happy to see the committee understanding that insulin is a life-sustaining therapy,” said Dave Prowten, President and CEO of JDRF Canada. “Canadians with type 1 diabetes spend up to $15,000 annually in out of pocket costs managing their disease. Access to the DTC would provide families some much-needed financial relief and we urge the Government to adopt the Committee’s recommendation.”
Continue –> GlobeNewsWire.com
